Cargando…

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nijland, Marcel, Veenstra, Rianne N., Visser, Lydia, Xu, Chuanhui, Kushekhar, Kushi, van Imhoff, Gustaaf W., Kluin, Philip M., van den Berg, Anke, Diepstra, Arjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414870/ https://www.ncbi.nlm.nih.gov/pubmed/28507804 http://dx.doi.org/10.1080/2162402X.2017.1295202

Ejemplares similares

HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
por: Huang, Xin, et al.
Publicado: (2012)

HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
por: Huang, Xin, et al.
Publicado: (2012)

PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma
por: Liu, Yuxuan, et al.
Publicado: (2013)

HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients
por: Tan, Geok Wee, et al.
Publicado: (2021)

Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma
por: Liang, Zheng, et al.
Publicado: (2014)

Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
por: Plattel, Wouter J., et al.
Publicado: (2020)

Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas
por: Wu, Rui, et al.
Publicado: (2016)

Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development
por: Jiang, Peijia, et al.
Publicado: (2021)

HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients
por: Fletcher, Luke B., et al.
Publicado: (2017)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

Relapse in stage I(E) diffuse large B‐cell lymphoma
por: Nijland, Marcel, et al.
Publicado: (2017)

Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
por: Huang, Xin, et al.
Publicado: (2010)

CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma
por: Sattarzadeh, Ahmad, et al.
Publicado: (2015)

Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Visser, Lydia, et al.
Publicado: (2016)

Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127
por: Sattarzadeh, Ahmad, et al.
Publicado: (2018)

Toll-like receptors in the pathogenesis of human B cell malignancies
por: Isaza-Correa, Johana M, et al.
Publicado: (2014)

The Microenvironment in Epstein–Barr Virus-Associated Malignancies
por: Tan, Geok Wee, et al.
Publicado: (2018)

Tumour necrosis as assessed with (18)F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
por: Kahle, Xaver U., et al.
Publicado: (2019)

Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2021)

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
por: McGranahan, Nicholas, et al.
Publicado: (2017)

Structural Modeling and Molecular Dynamics of the Immune Checkpoint Molecule HLA-G
por: Arns, Thais, et al.
Publicado: (2020)

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
por: Engelsen, Agnete S. T., et al.
Publicado: (2022)

HLA-G: A New Immune Checkpoint in Cancer?
por: Krijgsman, Daniëlle, et al.
Publicado: (2020)

The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells
por: Liu, Lu, et al.
Publicado: (2020)

Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer
por: Ding, Yi, et al.
Publicado: (2022)

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
por: Tian, Yaru, et al.
Publicado: (2020)

Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
por: Dutta, Shovan, et al.
Publicado: (2023)

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
por: de Jong, Mathilde R. W., et al.
Publicado: (2018)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020)

Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma
por: Fangazio, Marco, et al.
Publicado: (2021)

P031: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
por: Veldman, Johanna, et al.
Publicado: (2022)

Escaping a checkpoint
por: LeBrasseur, Nicole
Publicado: (2006)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
por: van de Donk, Pim P., et al.
Publicado: (2021)

The HLA-G Immune Checkpoint Plays a Pivotal Role in the Regulation of Immune Response in Autoimmune Diseases
por: Zaborek-Łyczba, Monika, et al.
Publicado: (2021)

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
por: Tian, Yaru, et al.
Publicado: (2019)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies
por: Morandi, Fabio, et al.
Publicado: (2022)

Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment
por: Yang, Yohan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8rnkdibucs6iigd0l5d71nk6pc